Kenji Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kenji Suzuki has a total of 343 co-authors. Here are the top co-authors by number of shared publications:
Takeshi Matsunaga
Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
72 shared publicationsKazuya Takamochi
Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
70 shared publicationsAritoshi Hattori
Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
65 shared publicationsShiaki Oh
Department of General Thoracic Surgery, Juntendo University School of Medicine , Tokyo, Japan
59 shared publications- Kazuya Takamochi
Department of General Thoracic Surgery, Juntendo University School of Medicine , Tokyo
54 shared publications Mariko Fukui
Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
42 shared publications
Latest Publications
- 27 October 2026
- Published by Springer Nature in Surgery Today
- p. 1-9
Surgical outcomes of patients with multifocal ground-glass opacities of the lungs located in the same pulmonary lobe
- 27 October 2026
- Published by Springer Nature in Surgery Today
- p. 1-9
Surgical outcomes of patients with multifocal ground-glass opacities of the lungs located in the same pulmonary lobe
- Open Access
- 26 October 2026
- Published by MDPI AG in Preprints.org
Analgesic Management of Robot-Assisted Surgery for Mediastinal Tumors: A Review of Pain Mechanisms, Regional Anesthesia, and Multimodal Analgesia
Background: Robot-assisted thoracic surgery (RATS) for mediastinal tumors is a minimally invasive approach that offers three-dimensional magnified visualization, tremor filtration, and articulated instruments. Although it is expected to reduce postoperative pain compared with open surgery, pain may still arise from intercostal ports, subxiphoid incisions and chest tubes. Therefore, a consistent multimodal analgesic strategy is needed from the intraoperative to the postoperative period, tailored to the surgical approach and port placement. Objective: This review aims to characterize the mechanisms underlying postoperative pain after RATS for mediastinal tumors and to examine the current evidence and clinical indications for systemic analgesics and regional analgesic techniques, including thoracic epidural analgesia (TEA), peripheral nerve blocks, and local wound infiltration. Conclusions: Routine use of TEA may not be necessary for all patients undergoing RATS for medi-astinal tumors. In most cases, a multimodal analgesic regimen based on acetaminophen, nonsteroidal anti-inflammatory drugs, or cyclooxygenase-2 selective inhibitors, supplemented with a single-shot regional block or local wound infiltration according to the surgical approach and port placement, appears reasonable. However, individualized analgesic strategies incorporating continuous regional analgesia should be considered in patients undergoing extensive thymectomy, those requiring ports across multiple intercostal spaces, those at risk of conversion to open surgery, and those with severe preoperative pain or an increased risk of chronic postoperative pain.
- 26 October 2026
- Published by MDPI AG in Preprints.org
Open AccessAnalgesic Management of Robot-Assisted Surgery for Mediastinal Tumors: A Review of Pain Mechanisms, Regional Anesthesia, and Multimodal Analgesia
Background: Robot-assisted thoracic surgery (RATS) for mediastinal tumors is a minimally invasive approach that offers three-dimensional magnified visualization, tremor filtration, and articulated instruments. Although it is expected to reduce postoperative pain compared with open surgery, pain may still arise from intercostal ports, subxiphoid incisions and chest tubes. Therefore, a consistent multimodal analgesic strategy is needed from the intraoperative to the postoperative period, tailored to the surgical approach and port placement. Objective: This review aims to characterize the mechanisms underlying postoperative pain after RATS for mediastinal tumors and to examine the current evidence and clinical indications for systemic analgesics and regional analgesic techniques, including thoracic epidural analgesia (TEA), peripheral nerve blocks, and local wound infiltration. Conclusions: Routine use of TEA may not be necessary for all patients undergoing RATS for medi-astinal tumors. In most cases, a multimodal analgesic regimen based on acetaminophen, nonsteroidal anti-inflammatory drugs, or cyclooxygenase-2 selective inhibitors, supplemented with a single-shot regional block or local wound infiltration according to the surgical approach and port placement, appears reasonable. However, individualized analgesic strategies incorporating continuous regional analgesia should be considered in patients undergoing extensive thymectomy, those requiring ports across multiple intercostal spaces, those at risk of conversion to open surgery, and those with severe preoperative pain or an increased risk of chronic postoperative pain.
- 9 October 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
Primary feasibility analysis of neoadjuvant chemotherapy with bevacizumab for resectable stage II/IIIA non-squamous non-small cell lung cancer: the NAVAL phase II study
Objectives: Bevacizumab (Bev) improves the response and survival rates in patients with advanced non-small cell lung cancer (NSCLC). This phase II trial aimed to assess the feasibility of adding Bev to preoperative chemotherapy in resectable non-squamous NSCLC. Methods: Patients with clinical stage II/IIIA non-squamous NSCLC (n = 30) received three cycles of cisplatin (Cis), pemetrexed (Pem), and Bev, followed by surgical resection. The primary endpoint was the complete resection rate (CRR), defined as the proportion of all eligible enrolled patients who ultimately underwent complete (R0) resection. The sample size was set at 30 patients. Treatment was considered feasible if the CRR exceeded the predefined acceptable threshold of 65%. Results: Radiological tumour reduction was observed in 29 of 30 patients (97%). Twenty-eight patients (93%) completed all three cycles of chemotherapy, and 25 patients (83%) underwent surgery. Five patients discontinued treatment due to adverse events (n = 3), disease progression (n = 1), or patient refusal (n = 1). Complete resection was achieved in all resected patients, yielding an 83% CRR (two-sided 80% confidence interval, 71.3%–91.7%). The objective response rate was 37%, and pathological complete response of the primary tumour was achieved in 3 patients (12%). Grade 3 toxicities included neutropenia (7%), nausea (7%), hypertension (23%), and pulmonary embolism (3%). No grade 4/5 adverse events occurred within 28 days, and no treatment-related deaths occurred within 84 days. Conclusions: Preoperative Cis, Pem, and Bev for clinical stage II/IIIA non-squamous NSCLC met the predefined feasibility criterion, with acceptable safety in this selected population. These findings provide historical insights supporting perioperative anti-vascular endothelial growth factor-based systemic intensification.
- 9 October 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
Primary feasibility analysis of neoadjuvant chemotherapy with bevacizumab for resectable stage II/IIIA non-squamous non-small cell lung cancer: the NAVAL phase II study
Objectives: Bevacizumab (Bev) improves the response and survival rates in patients with advanced non-small cell lung cancer (NSCLC). This phase II trial aimed to assess the feasibility of adding Bev to preoperative chemotherapy in resectable non-squamous NSCLC. Methods: Patients with clinical stage II/IIIA non-squamous NSCLC (n = 30) received three cycles of cisplatin (Cis), pemetrexed (Pem), and Bev, followed by surgical resection. The primary endpoint was the complete resection rate (CRR), defined as the proportion of all eligible enrolled patients who ultimately underwent complete (R0) resection. The sample size was set at 30 patients. Treatment was considered feasible if the CRR exceeded the predefined acceptable threshold of 65%. Results: Radiological tumour reduction was observed in 29 of 30 patients (97%). Twenty-eight patients (93%) completed all three cycles of chemotherapy, and 25 patients (83%) underwent surgery. Five patients discontinued treatment due to adverse events (n = 3), disease progression (n = 1), or patient refusal (n = 1). Complete resection was achieved in all resected patients, yielding an 83% CRR (two-sided 80% confidence interval, 71.3%–91.7%). The objective response rate was 37%, and pathological complete response of the primary tumour was achieved in 3 patients (12%). Grade 3 toxicities included neutropenia (7%), nausea (7%), hypertension (23%), and pulmonary embolism (3%). No grade 4/5 adverse events occurred within 28 days, and no treatment-related deaths occurred within 84 days. Conclusions: Preoperative Cis, Pem, and Bev for clinical stage II/IIIA non-squamous NSCLC met the predefined feasibility criterion, with acceptable safety in this selected population. These findings provide historical insights supporting perioperative anti-vascular endothelial growth factor-based systemic intensification.
- 17 September 2026
- Published by Springer Nature in Surgery Today
- p. 1-11
Predictive significance of preoperative prognostic nutritional index after surgery for clinical T4 lung cancer
- 17 September 2026
- Published by Springer Nature in Surgery Today
- p. 1-11
Predictive significance of preoperative prognostic nutritional index after surgery for clinical T4 lung cancer
- 13 June 2026
- Published by Springer Nature
- p. 87-94
Evolution of Mode of Surgery for Lung Cancer: Historical Moment
- 13 June 2026
- Published by Springer Nature
- p. 87-94
Evolution of Mode of Surgery for Lung Cancer: Historical Moment
- Open Access
- 31 May 2026
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2026 (6) , rjag153
Challenges and strategies for robotic portal anatomical resection in patients with thoracic deformities
Anatomical resection using a robotic approach in patients with thoracic deformities presents several challenges, including port placement. We present two patients with thoracic deformities—one without (Case 1) and one with (Case 2) specific port placements—focusing on difficulties such as limited visibility and restricted motion of the robotic arm.
- 31 May 2026
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2026 (6) , rjag153
Open AccessChallenges and strategies for robotic portal anatomical resection in patients with thoracic deformities
Anatomical resection using a robotic approach in patients with thoracic deformities presents several challenges, including port placement. We present two patients with thoracic deformities—one without (Case 1) and one with (Case 2) specific port placements—focusing on difficulties such as limited visibility and restricted motion of the robotic arm.
- Open Access
- 26 May 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (6) , e72605
Intrathoracic Extramedullary Hematopoiesis Arising in the Anterior Mediastinum
Anterior mediastinal extramedullary hematopoiesis (EMH) is rare and can mimic thymic tumors. Slow growth rate and evolving fat content should prompt inclusion of EMH in the differential diagnosis and caution regarding biopsy/invasive procedures in hypervascular lesions. Histologic confirmation is desirable to obtain a definitive diagnosis and guide management.
- 26 May 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (6) , e72605
Open AccessIntrathoracic Extramedullary Hematopoiesis Arising in the Anterior Mediastinum
Anterior mediastinal extramedullary hematopoiesis (EMH) is rare and can mimic thymic tumors. Slow growth rate and evolving fat content should prompt inclusion of EMH in the differential diagnosis and caution regarding biopsy/invasive procedures in hypervascular lesions. Histologic confirmation is desirable to obtain a definitive diagnosis and guide management.